Galloway-Mowat syndrome (GAMOS) is an autosomalrecessive disease characterized by the combination of earlyonset nephrotic syndrome (SRNS) and microcephaly with brain anomalies. Here we identified recessive mutations in OSGEP, TP53RK, TPRKB, and LAGE3, genes encoding the four subunits of the KEOPS complex, in 37 individuals from 32 families with GAMOS. CRISPR-Cas9 knockout in zebrafish and mice recapitulated the human phenotype of primary microcephaly and resulted in early lethality. Knockdown of OSGEP, TP53RK, or TPRKB inhibited cell proliferation, which human mutations did not rescue. Furthermore, knockdown of these genes impaired protein translation, caused endoplasmic reticulum stress, activated DNA-damage-response signaling, and ultimately induced apoptosis. Knockdown of OSGEP or TP53RK induced defects in the actin cytoskeleton and decreased the migration rate of human podocytes, an established intermediate phenotype of SRNS. We thus identified four new monogenic causes of GAMOS, describe a link between KEOPS function and human disease, and delineate potential pathogenic mechanisms.
in 907 individuals with nephrotic syndrome, including 91 individuals with GAMOS. We discovered mutations in these four genes in 37 individuals with GAMOS from 32 different families (Supplementary Table 1 and Supplementary Figs. 1-3) . Inheritance was autosomal recessive or X-chromosome linked (LAGE3). Multiple OSGEP mutations were shared among different families of distinct ancestry, thus probably representing geographic founder alleles from Iran, Taiwan, and Europe (Supplementary Table 1) .
Phenotypically, with the exception of those in families KW and PN553, all individuals with mutations in any of the four genes encoding KEOPS subunits had primary microcephaly, developmental delay, a propensity for seizures, and nephrotic syndrome with early onset (Fig. 1, Table 1 , Supplementary Fig. 4 and Supplementary Table 1) . Most affected individuals died in early childhood. Several individuals were found to have facial dysmorphism, including a small, narrow forehead, large/floppy ears, deep-set eyes, hypertelorism, and micrognathia, as well as skeletal abnormalities such as arachnodactyly. The most frequently observed brain anomalies included a spectrum of gyration abnormalities ranging from lissencephaly to pachygyria and polymicrogyria, and cerebellar hypoplasia (Fig. 1, Table 1 , Supplementary Fig. 4 and Supplementary Table 1) .
Renal biopsy showed focal-segmental glomerulosclerosis (FSGS), its developmental equivalent, diffuse mesangial sclerosis 18 , or other glomerular lesions in 19 individuals in whom a renal biopsy was performed. Electron microscopy showed partial podocyte footprocess effacement (Fig. 1, Table 1, Supplementary Fig. 4 and Supplementary Table 1) . Independently, another group has recently also identified a homozygous mutation of OSGEP in a patient with a similar renal-neurological phenotype 19 .
To evaluate the pathogenic effects of KEOPS-protein loss of function in an in vivo animal model, we performed CRISPR-Cas9 knockout of the orthologous zebrafish genes osgep and tprkb. Knockout of osgep (Supplementary Fig. 5 ) or tprkb ( Supplementary Fig. 6 ) in zebrafish larvae recapitulated a primary microcephaly phenotype, as is found in humans with mutations in genes encoding KEOPS subunits. Using TUNEL staining, we observed marked apoptosis in the brain (telencephalon) in osgep-knockout and to a lesser extent tprkb-knockout zebrafish compared with age-matched clutchmates (Supplementary Fig. 7 ). Because most patients with OSGEP mutations died in early childhood, we generated Kaplan-Meier survival curves for zebrafish with CRISPR-Cas9 knockout of osgep or tprkb and found that knockout fish showed early lethality (15 or 18 d post fertilization, respectively) ( Supplementary Fig. 8 ).
l e t t e r s 
l e t t e r s
Mouse embryos with CRISPR-Cas9 knockout of Lage3, Osgep, or Tprkb had significantly shorter cortex lengths, cortex-midbrain midline lengths, and cortex widths than those in wild-type embryos, and thus reproduced the human phenotype of primary microcephaly ( Supplementary Figs. 9 and 10) . We did not observe a renal phenotype in knockout mice or fish, possibly as a result of early lethality masking renal involvement that might have occurred in older animals.
Using the available crystal structures of homologous subassemblies of the KEOPS complex [20] [21] [22] , we constructed a 3D model of the human complex and projected the various human mutations onto this model (Fig. 2a) . Using yeast depleted of kae1, the ortholog of OSGEP, in a yeastbased functional growth complementation assay (Fig. 2b) , we identified two functional classes of OSGEP mutant alleles: (i) hypomorphic alleles that restored growth but to a lesser extent than wild-type OSGEP and (ii) amorphic alleles that were completely unable to restore growth.
Furthermore, we showed by coimmunoprecipitation experiments that the truncating alteration p.Lys60Serfs*61 and the missense alteration p.Thr81Arg of TP53RK (NM_033550.3) detected in family B77 both abrogated the interaction between TPRKB and TP53RK (Fig. 2c) .
Other mutations in any of the four genes did not abrogate intermolecular interactions (Supplementary Figs. 11-13) .
We evaluated the subcellular localization of all four KEOPS proteins, as either endogenous proteins or overexpressed Myc-or GFP-tagged proteins. We found that all four proteins localized to both the cytoplasm and the nucleus in podocyte cell lines (Supplementary Figs. 14  and 15) . Furthermore, we demonstrated by mass spectrometry in a Fig. 16 ). Genetic deletion of genes encoding KEOPS subunits results in severe growth defects in yeast 13 . We therefore tested whether knockdown of OSGEP, TP53RK, or TPRKB also altered proliferation of mammalian cells and, by using a bromodeoxyuridine (BrdU) assay (Fig. 2d) and the XCELLigence system (Supplementary Fig. 17a ), we found that short hairpin RNA (shRNA) knockdown of these genes in human podocytes impaired the cell proliferation rate. The proliferation defect was rescued by reexpression of wild-type but not mutant cDNA (Fig. 2e,f and Supplementary Fig. 17b ), thus indicating that the identified human disease alleles impair protein functionality.
The canonical function of the KEOPS complex is to mediate N 6 -threonylcarbamoyladenosine modification, known as t 6 A modification, at position 37 of all tRNAs recognizing codons that start with adenosine, i.e., ' ANN codons' [7] [8] [9] [10] . Using mass spectrometry, we Cell proliferation rate BrdU incorporation after 6 h (absorbance at 450 nm) OSGEP mutations can be classified into two types: hypomorphic alleles (encoding p.Lys198Arg, p.Arg247Gln, p.Arg280Leu, and p.Arg325Gln) and amorphic alleles (encoding p.Ile14Phe, p.Ile111Thr, and p.Cys110Arg). The result was confirmed in two additional independent experiments. (c) Coimmunoprecipitation (IP) of FLAG-tagged full-length, wild-type (WT) TPRKB with GFP-tagged wild-type TP53RK or mutant TP53RK cDNA constructs that reflect the GAMOS mutations. Constructs reflecting the TP53RK mutants p.Lys60Serfs*61 and p.Thr81Arg abrogate interaction with TPRKB. Displayed membranes are cropped. The result was confirmed in three independent experiments (additional data in supplementary Fig. 11 ). MW, molecular weight. (d) A colorimetric BrdU assay demonstrating lower cell proliferation rates in human podocytes with shRNA knockdown of OSGEP, TP53RK, or TPRKB than in those expressing scrambled-control shRNA. Individual data points are derived from two independent experiments and are displayed with mean and s.d. Statistical analysis was performed using two-tailed one-way ANOVA (F (6,7) = 21.6, P = 0.0003). P values derived from Sidak's multiple comparisons test are shown. Scrambled-control shRNA and various shRNA sequences (denoted with 'sh') are indicated. (e,f) Proliferation rate of human immortalized podocytes, assayed with the xCELLigence system. One representative experiment is shown. The result was confirmed in a total of three independent cell culture experiments. Data points represent the mean value of three technical replicates for each condition. Error bars, s.d. (e) OSGEP knockdown (red line) decreased the podocyte proliferation rate, and this effect was rescued by stable overexpression of mouse wild-type, full-length Osgep (green) but not of mutant constructs reflecting the mutations identified in individuals with GAMOS. (f) TP53RK knockdown (red line) decreased the podocyte proliferation rate, and this effect was rescued by stable overexpression of mouse wild-type, full-length Tp53rk (green) but not of mutant Tp53rk constructs reflecting the mutations identified in individuals with GAMOS. l e t t e r s demonstrated that t 6 A levels in human podocytes were significantly lower after knockdown of OSGEP but not TPRKB (Fig. 3a) . We determined that, compared with wild-type OSGEP cDNA, constructs bearing GAMOS mutations were less able to restore t 6 A levels in yeast depleted of kae1, the OSGEP ortholog (Fig. 3b) . In line with the results of the growth complementation assay, we identified hypomorphic as well as amorphic alleles. The absence of t 6 A modifications in yeast decreases translational accuracy and efficiency 8, 23 . We therefore studied the consequences of knockdown of genes encoding KEOPS subunits on protein translation in human podocytes. Using two different colorimetric assay systems based on incorporation of O-propargylpuromycin (OPP) or L-homopropargylglycine (HPG), we demonstrated significantly lower de novo protein biosynthesis in human podocytes expressing OSGEP, TP53RK, or TPRKB shRNA than in those expressing scrambled-control nontargeting shRNA (Fig. 3c,d) . We thereby demonstrated a primary impairment in protein biosynthesis resulting from loss of function of KEOPS proteins; this impairment is likely to contribute to the observed decrease in cell proliferation The results were confirmed in three independent cell culture experiments. β-actin, loading control. (f) Proteasome activity, assessed with an AMC-tagged peptide substrate that releases the fluorescent substrate AMC in the presence of proteolytic activity. Fluorescence intensity was normalized to an internal standard to calculate proteasome activity. Podocytes expressing OSGEP, TP53RK, or TPRKB shRNAs displayed higher proteasome activity than those expressing scrambled shRNA. (F (6, 14) = 12.13, P < 0.0001).
l e t t e r s rate ( Fig. 2d and Supplementary Fig. 17a ) but might also cause other secondary cellular defects, as described below. Translational errors can impair protein folding, thus causing endoplasmic reticulum (ER) stress with subsequent activation of the unfolded protein response (UPR) 24, 25 . We performed immunoblotting in podocytes with shRNA knockdown of OSGEP, TP53RK, or TPRKB and found an increase in phosphorylated IRE1α, spliced XBP-1 (XBP-1s), phosphorylated eIF2α, and ATF4, thus indicating activation of the UPR (Fig. 3e) . The observed hyperphosphorylation of eIF2α, which mediates translational attenuation during ER stress, probably contributed to the observed decrease in protein biosynthesis in knockdown cells (Fig. 3c,d ). Using a 7-amino-4-methylcoumarin (AMC)-based colorimetric assay, we further showed that knockdown of OSGEP, TP53RK, or TPRKB in human podocytes increased proteasomal activity, thus probably indicating upregulation of the ER-associated proteasomal degradation system after chronic ER stress 26 (Fig. 3f) .
We observed that, after four or five passages, immortalized human podocytes with stable shRNA knockdown of OSGEP, TP53RK, or TPRKB exhibited severely decreased cell survival and increased apoptosis, as demonstrated by elevated caspase-3 activity (Fig. 4a) . Because the KEOPS complex has been implicated in genome maintenance 14, 15 , we tested whether the observed induction of apoptosis could be elicited by activation of DDR signaling. We found that shRNA knockdown of OSGEP, TP53RK, or TPRKB in immortalized human podocytes increased immunofluorescence staining for phosphorylated . Absolute values were normalized to β-actin (loading control). Intensities of cells expressing scrambled-control shRNA were normalized to 1. For better visualization, a trendline was added to the graph. Knockdown of OSGEP resulted in an increase in γH2AX and p21 on days 5, 7, and 9 after knockdown. In contrast, BAX and cleaved caspase-3 showed strong induction on only days 7 and 9 after knockdown, thus demonstrating that the activation of the DDR (γH2AX) precedes the induction of apoptosis (BAX, cleavage of caspase-3) after knockdown of OSGEP. The decrease in signals for γH2AX, p21, and BAX on dayl e t t e r s histone H2AX (γH2AX), thereby indicating DDR activation ( Fig. 4b and Supplementary Fig. 18a) . We confirmed the increase in γH2AX by immunoblotting in knockdown podocyte cell lines (Fig. 4c,d and Supplementary Fig. 19 ) and in fibroblasts from patients with GAMOS and mutations in OSGEP or TPRKB (Supplementary Fig. 18b ).
To elucidate the sequence of DDR activation and induction of apoptosis, we performed immunoblotting of γH2AX and caspase-3 at three different time points after shRNA knockdown of OSGEP in a human podocyte cell line (Fig. 4c,d) . We found increased protein levels of γH2AX and the CDK inhibitor p21 on days 5, 7, and 9 after knockdown.
In contrast, the proapoptotic factor BAX and cleaved caspase-3 showed strong induction on only days 7 and 9 ( Fig. 4c,d) . The time course suggested that, as expected, γH2AX activation preceded the induction of apoptosis. Induction of γH2AX, p21, BAX, and caspase-3 was also found in podocytes with shRNA knockdown of TP53RK or TPRKB (Supplementary Fig. 19 ). We further confirmed the genomic instability in KEOPS-knockdown cells by showing that the genotoxic agent mitomycin-C induced apoptosis in OSGEP-, TP53RK-, or TPRKB-knockdown cell lines at concentrations that did not affect control cells (Supplementary Fig. 20) . OSGEP sh#2 Supplementary Figs. 21 and 22) and found that TP53RK colocalized with the DNA-repair protein PARP1 in renal glomeruli (Fig. 4e) . Similarly, we observed colocalization of OSGEP and PARP1 in a human podocyte cell line (Supplementary Fig. 22c) . Coimmunoprecipitation experiments demonstrated that all four members of the KEOPS complex molecularly interact with PARP1 (Fig. 4f) .
Microcephaly, a feature common to various syndromes of defective DDR [27] [28] [29] [30] , is probably due to increased apoptosis of neuronal progenitor cells. Furthermore, podocyte loss has been described as an important pathomechanism of renal glomerulosclerosis 31 . We therefore propose that induction of DDR and increased apoptosis are likely to be integral in the pathogenesis of GAMOS in individuals with mutations in genes encoding KEOPS subunits. Although yeast depleted of KEOPS subunits exhibit shortened telomeres 32 , the telomere length in affected children was found to be in the normal range (Supplementary Fig. 23) .
After epidermal growth factor (EGF) stimulation, OSGEP and TP53RK have been suggested to interact with proteins of the ARP2/3 complex 33 , which are essential regulators of actin remodeling at lamellipodia 34 . Lamellipodia formation and actin remodeling are important cellular functions of podocytes that are impaired in monogenic forms of SRNS 35 . We confirmed by coimmunoprecipitation that OSGEP and TP53RK interact with proteins of the ARP2/3 complex (Fig. 5a-c and Supplementary Fig. 24 ) and observed that OSGEP and TP53RK colocalized with ARP2 and ARP3 at lamellipodia in human podocytes (Fig. 5d) . Interestingly, after shRNA knockdown of OSGEP or TP53RK, the formation of the sublamellipodia actin network in immortalized human podocytes was severely disrupted (Fig. 5e) .
We furthermore found that podocyte migration, a well-established surrogate phenotype of SRNS [36] [37] [38] , was decreased in podocytes with knockdown of OSGEP, TP53RK, or TPRKB (Fig. 5f) . We concluded that alterations in the actin cytoskeleton contribute to the pathogenesis of nephrotic syndrome caused by mutations in genes encoding KEOPS subunits, and we propose that these defects are not exclusively secondary to translational defects but are partially elicited by an interaction between KEOPS proteins and components of the ARP2/3 complex.
In conclusion, we demonstrated that specific mutations in genes encoding the four subunits of the KEOPS complex are newly identified monogenic causes of GAMOS, and we introduce the terms 'GAMOS 2-5' for GAMOS caused by mutations in LAGE3, OSGEP, TP53RK, and TPRKB, respectively. We delineated impaired cell proliferation, translational attenuation, ER stress, activation of DDR signaling, increased apoptosis, and defects in actin regulation as possible pathogenic features.
URLs. CHOPCHOP, https://chopchop.rc.fas.harvard.edu/; Sequence Scan for CRISPR, http://crispr.dfci.harvard.edu/SSC/; CRISPR Design, http://crispr.mit.edu/; Phyre server, http://www.sbg.bio. ic.ac.uk/phyre2/html/; Perseus software version 1.5.5.3 http://www. perseus-framework.org/.
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ONLINE MEtHODS
Study participants. We obtained blood samples and pedigrees after obtaining informed consent from individuals with nephrotic syndrome/GAMOS or their legal guardians. Approval for research on human subjects was obtained from the Institutional Review Boards of the University of Michigan, Boston Children's Hospital, the University of Erlangen, and the Comité de Protection des Personnes Ile de France II. Phenotypic assessment of 91 patients with GAMOS who were screened for mutations in LAGE3, OSGEP, TP53RK, or TPRKB showed no overt phenotypic differences between patients with mutations in these genes and patients in whom no mutations were detected.
Homozygosity mapping and whole-exome sequencing. WES was performed as previously described 5 with Agilent SureSelect human exome capture arrays (Thermo Fisher Scientific) with next-generation sequencing (NGS) on an Illumina platform. Sequence reads were mapped against the human reference genome (NCBI build 37/hg19) with CLC Genomics Workbench (version 6.5.1) (CLC bio). For homozygosity mapping, downstream processing of aligned BAM files was done with Picard and samtools 39 . SNV calling was done with GATK5, and the generated VCF file was subsequently used in homozygosity mapper 40 . Genetic regions of homozygosity by descent were plotted across the genome as candidate regions for recessive genes, as previously described 4 . Mutation calling was performed in line with proposed guidelines 41 produced by scientists with knowledge of clinical phenotypes, pedigree structure, and genetic mapping.
High-throughput mutation analysis by array-based multiplex PCR and NGS. We used the 48.48 Access Array microfluidic technology (Fluidigm) to perform barcoded multiplex PCR, as described previously 17, 42 . A total of 91 individuals with nephrotic syndrome and brain anomalies as well as 816 individuals with isolated nephrotic syndrome were sequenced. 2 × 250-bp paired-end sequencing was performed on an Illumina MiSeq instrument. Sequence alignment was conducted with CLC Genomics Workbench (CLC bio). Mutations were confirmed by Sanger sequencing and evaluated for segregation.
Generation and phenotypic characterization of stable zebrafish knockout lines by CRISPR-Cas9. Target selection and sgRNA generation. Single guide RNA (sgRNA) targets were selected with the CHOPCHOP online tool (URLs) 43 according to a ranking algorithm that takes into account all potential off-targets differing in up to 2 nt, GC content, and the presence of a guanine residue in the last position before the protospacer-adjacent-motif sequence, because these factors influence the efficiency of sgRNA binding and Cas9 cleavage 44 . Targets were chosen in the early exons to potentially introduce early frameshift mutations to maximize loss of function of the protein. gRNAs were generated by in vitro transcription from oligonucleotide-based templates with a MEGAscript T7 Transcription kit (Ambion) as previously described 45 . Because gRNA activity is higher if two guanine bases follow the T7 promoter, template sequences were modified accordingly if necessary. The resulting change of one or two nucleotides at the 5′ end of the gRNA results in a higher indel frequency 44 and does not decrease specificity 45 .
Microinjection, mutation analysis and breeding. 2 µl of sgRNA stock (500 ng/µl) was mixed with 2 µl of recombinant Cas9 protein (1 µg/µl, PNA Bio) and incubated on ice for at least 10 min to allow formation of the sgRNA/ Cas9 complex. 2 nl of the injection mix was injected intracellularly in one-cellstage zebrafish embryos by using glass needles and a micromanipulator. DNA was extracted from ten pooled injected embryos and an uninjected control group at 48 h post fertilization by using the HotShot protocol 46 . Mutagenesis was determined by a T7 endonuclease assay as previously described 47 . Positive clutches (F 0 generation) were raised to adulthood and outcrossed against wildtype fish. Germline transmission was also determined by T7 endonuclease assays. Positive clutches (F 1 generation) were raised to adulthood and genotyped individually. Fish carrying the same mutation were pooled and served as founders of the heterozygous stable-knockout line.
Microcephaly assay in zebrafish. Zebrafish larvae at 4 d post fertilization (dpf) were embedded in 1% agarose and imaged from a dorsal view. The total body length and head diameter through the rear third of the eye lens were measured with ImageJ by an investigator blinded to the genotype. The head diameter/total body length ratio was calculated as an index of microcephaly.
Significant differences were calculated with one-way ANOVA with multiple comparisons and a standard confidence interval of 95%.
Zebrafish experiments were performed in Danio rerio, strain l-fabp: VDBP-GFP (AB). All national and institutional guidelines for the care and use of laboratory animals were followed. The zebrafish experiments were approved by the Boston Children's Hospital (BCH) Institutional Animal Care and Use Committee (IACUC).
TUNEL staining in zebrafish. Zebrafish larvae were euthanized at 3 dpf or 5 dpf, fixed in 4% PFA in PBS overnight at 4 °C, and embedded in paraffin after dehydration in an ethanol series and xylene. After rehydration, TUNEL staining was performed with an In SituI Cell Death Detection Kit, Fluorescein (Roche) according to the manufacturer's instructions. Slides were counterstained with DAPI to visualize cell nuclei, and images were taken on a compound microscope equipped with a monochromatic fluorescence camera (Nikon).
Generation and phenotypic characterization of transient KEOPS-mutant mouse embryos by CRISPR-Cas9. The mouse genomic regions equivalent to the human mutations in LAGE3 (encoding p.Phe137Ser), OSGEP (encoding p.Ile14Phe), TP53RK (encoding p.Arg243Leu), and TPRKB (encoding p.Leu136Pro) were analyzed for CRISPR-Cas9 target sites with the software package Sequence Scan for CRISPR (URLs), and the optimized CRISPR Design tool (URLs). Four different sgRNAs, each targeting a different gene encoding a KEOPS subunit, were selected on the basis of their efficiency scores and low off-target effects. sgRNAs were synthesized in vitro through standard procedures, and Cas9 mRNA was purchased from Sigma (Cas9mRNA-1EA). A mix of sgRNA (100 ng/µL) and Cas9mRNA (100 ng/µL) for each gene, or a scrambled sgRNA for control embryos (WT), was co-injected into the cytoplasm in fertilized eggs and transferred into pseudopregnant females. All CRISPR injections were performed in C57BL/6 oocytes. Transient CRISPR/Cas9 E 18.5 embryos were recovered and analyzed for microcephaly phenotypes. Brain cortex lengths, cortex-midbrain midline lengths and cortex widths were determined with Image J. Each embryo obtained from the CRISPR injection was assigned a number, and brain morphology measurements were performed by an investigator blinded to the genotype). Subsequently, the occurrence of gene editing was confirmed by PCR amplification from extracted genomic DNA and subsequent Sanger sequencing. Targeting efficiency was quantified with the Tracking of Indels by Decomposition (TIDE) web tool 48 . Measurements from embryos injected with scrambled sgRNA and from embryos with LAGE3, OSGEP, TP53RK, and TPRKB targeted were then grouped, and graphs were generated with GraphPad Prism software version 6.0. After genotyping, nontargeted embryos (with ineffective sgRNA targeting) were excluded from the graph. Unpaired Student's t-tests were used to test for differences between the means. CRISPR experiments in mice were performed according to the guidelines of the Canadian Council on Animal Care, after approval by the McGill Animal Care Committee. 3D modeling. 3D models of the human KEOPS complex were obtained with the Phyre server (URLs) 49 . The highest-confidence models were retrieved for the LAGE3, OSGEP, and TP53RK components. The structure of the human TPRKB protein is available in the Protein Data Bank (PDB 3ENP). The model of the human KEOPS was constructed by superposing the structures of the human subunits onto the archaeal Pcc1-Kae1 (PDB 3ENO) and Kae1-Bud32 (PDB 3VWB) and the fungal Bud32-Cgi121 (PDB 4WW9) subcomplexes. The sequences and structures of the interfaces between the subunits are well conserved. The LAGE3 p.Phe137Ser and TP53RK p.Gly42Asp alterations were not located in sequence regions that could be confidently modeled and are therefore are not represented in Figure 2a .
Heterologous complementation assay of yeast kae1 mutant. The haploid conditional yeast kae1-mutant strain (DL344) was derived from the W303 genetic background and contained a genomic deletion of the KAE1 gene complemented by a URA3-plasmid-borne KAE1 wild-type allele (kindly provided by D. Libri). Human cDNAs encoding wild-type or mutant OSGEP were cloned in the yeast multicopy vector pESC-TRP1 (Agilent Technologies) under the control of the yeast strong inducible promoter P GAL10 . Native pESC-TRP1 plasmid and a pFL39 plasmid carrying the yeast wild-type KAE1 gene were used as negative and positive controls, respectively. The various plasmids were introduced in the kae1-mutant strain. After selection on glucose-Trp solid medium, transformant clones were streaked onto Gal-Trp + 5FOA medium to chase out the URA3-KAE1 plasmid. Serial dilutions of cell suspensions prepared from colonies growing on 5FOA plates were spotted on Gal-Trp medium and incubated at 28 °C to monitor growth complementation. Expression of human OSGEP constructs was confirmed by western blotting with an anti-OSGEP antibody (HPA039751, Sigma Life Science) (Supplementary Fig. 25 ).
Proteomic studies. A human podocyte cell line stably expressing the human LAGE3 subunit fused to an N-terminal V5 epitope was used to perform proteomic studies. Coimmunoprecipitation was performed with a µMACS Protein A Microbeads Isolation Kit (Miltenyi Biotec) to isolate V5-tagged LAGE3. The immunoprecipitation eluates were processed by FASP as previously described 50 . Peptides were dried in a SpeedVac and resuspended in 10% acetonitrile and 0.1% TFA before MS analysis with a nanoRSLC-Q Exactive Orbitrap Plus instrument (Dionex RSLC Ultimate 3000, Thermo Fisher Scientific). Raw files were analyzed with MaxQuant 1.5.5.1 software 50 against the Human UniProt KB/Swiss-Prot database 2016-01. The false discovery rates (FDRs) at the protein and peptide levels were set to 1%. Scores were calculated in MaxQuant as previously described 51 . Statistical and bioinformatic analysis, including construction of volcano plots, were performed with Perseus software version 1.5.5.3 (URLs) 52 . For statistical comparison, two groups were set up, each containing three biological replicates: control IP and IP LAGE3. Only proteins that were quantified at least three times out of six were retained. A t-test was performed, and the data were represented in volcano plots (FDR <0.01, S0 = 2, 250 randomizations) (Supplementary Fig. 16 ). 
Coimmunoprecipitation.
For coimmunoprecipitation experiments, cell lysates were incubated overnight at 4 °C in lysis buffer with beads conjugated to the appropriate primary antibody (primary antibodies are listed in Supplementary  Table 2 ). Beads were washed five times with lysis buffer before elution and immunoblotting. Coimmunoprecipitation of GFP-fusion proteins was performed with Chromotek-GFP-Trap Agarose Beads (Allele Bioscience). Coimmunoprecipitation of Myc-and FLAG-tagged fusion proteins was performed with EZview Red Antic-Myc and EZview Red FLAG M2 Affinity Gel (Sigma Aldrich). All immunoprecipitation experiments were performed three times independently, and images shown herein are representative of all results.
RNAi knockdown in human podocyte cell lines. pSirenRetroQ with shRNA targeting human OSGEP, TP53RK, or TPRKB (shRNA sequences are listed in Supplementary Table 3) , or control scrambled (nontargeting) shRNA was used for retroviral transduction of immortalized human podocyte cell lines 53 (obtained from M. Saleem). HEK293T cells for virus production were purchased from ATCC. Cell lines were tested monthly for mycoplasma contamination. Puromycin was used to select for transduced cells. Owing to growth defects, knockdown cells deteriorated after passages four or five (typically 12-14 d after transduction). Knockdown efficiency was confirmed for all experiments ( Supplementary  Fig. 26 ). For rescue experiments, knockdown podocytes were subjected to a second lentiviral transduction with mouse mutant or wild-type cDNA of Osgep, Tp53rk, or Tprkb (expression control is shown in Supplementary Fig. 27 ).
Immunofluorescence and confocal microscopy in cell lines and tissue sections. Immunostaining was performed in immortalized human podocyte cell lines and paraffin-embedded tissue sections (rat kidney, day 1 postpartum). Overexpression experiments were performed 24-48 h after transfection with mass spectrometer in dynamic multiple reaction monitoring (MRM) mode. Modified nucleosides were identified on the basis of the presence of the correct retention time and mass transition. Under our chromatography conditions, t 6 A eluted at 8.1 min with a mass transition of m/z →413281.
Data analysis. MS signals for t 6 A were corrected for total RNA content, HPLC injection volume and MS fluctuations in two ways. First, peaks corresponding to the detection of the MRM transition for t 6 A were first normalized to the peak area of the internal standard ([ 15 N]2-deoxyadenosine) to account for intersample detection fluctuations. Second, these corrected signals were then normalized against the sum of the UV-detector peak areas (260 nm) for the four canonical ribonucleosides (cytidine, uridine, guanosine, and adenosine) to correct for variations in HPLC injection volume and RNA content. Samples derived from two independent experiments were each measured twice (two technical replicates).
Protein synthesis assay (O-propargyl-puromycin based).
The Cayman protein synthesis assay system (cat. no. 601100) was used according to the manufacturer's instructions. Briefly, 4.5 × 10 4 immortalized human podocytes expressing OSGEP, TP53RK, TPRKB or scrambled-control shRNAs were seeded in 96-well plates. After addition to the culture medium, OPP, an alkyne-containing puromycin analog, incorporates into the C terminus of growing polypeptide chains. After 30 min, alkyne-labeled proteins were stained with 5-FAM-azide, and subsequently the fluorescence intensity at 485/535 nm was measured with a microplate reader (GloMax-Multi Detection System, Promega). Fluorescence intensities for knockdown cells were normalized to that of the internal control. Each experiment included three technical replicates that were averaged. The experiment was repeated in three independent cell culture experiments.
Protein synthesis assay (l-homopropargylglycine based). We used 4.5 × 10 4 immortalized human podocytes expressing OSGEP, TP53RK, TPRKB or scrambled-control shRNAs and performed Click-iT HPG Alexa Fluor 488 Protein Synthesis Assays (C10428, Thermo Fisher) according to the manufacturer's instructions. HPG, an alkyne-containing analog of the amino acid methionine was incorporated into newly synthesized proteins during active protein biosynthesis. After 30 min, alkyne-labeled proteins were stained, and the fluorescence intensity (Alexa Fluor 488) was measured with a microplate reader (GloMax-Multi Detection System, Promega). Fluorescence intensities for knockdown cells were normalized to that of the internal control. Each experiment included three technical replicates that were averaged. The experiment was repeated in three independent cell culture experiments.
Proteasome activity assay. A proteasome Activity Assay Kit (ab107921, Abcam) was used according to the manufacturer's instructions. Briefly, immortalized human podocytes expressing OSGEP, TP53RK, TPRKB, or scrambled-control shRNAs were lysed in 0.5% NP-40. Subsequently, the protein concentration was measured, and equal amounts of protein (10 µg) were used for the analysis. Each condition was measured in duplicate, and proteasome activity was assessed over a period of 30 min. In this assay, proteasome activity was determined on the basis of an AMC-tagged peptide substrate that releases the fluorescent substrate AMC in the presence of proteolytic activity. The fluorescence intensity (350/440 nm) was measured with a microplate reader (GloMax-Multi Detection System, Promega). Subsequently, the detected fluorescence intensity was normalized to an internal standard to calculate absolute proteasome activity. The experiment was performed three times independently (cell culture replicates).
Apoptosis assay and treatment with mitomycin-C. Apoptosis in human podocyte cell lines with shRNA knockdown of OSGEP, TP53RK, or TPRKB was assessed with a colorimetric Caspase 3 Assay Kit (ab39401, Abcam) according to the manufacturer's instructions. Caspase-3 activity was measured as absorbance at 405 nm with a spectrophotometer GloMax-Multi Detection System, Promega). Each experiment included two technical replicates, and the experiment was repeated three times independently (with cell culture replicates). For mitomycin-C (MMC) experiments, knockdown and control cells were treated with MMC (2.5 µg/ml) 12 h before the experiment.
Podocyte migration assays. The migration rate of human podocyte cell lines with retroviral shRNA knockdown of OSGEP, TP53RK, or TPRKB (5 d after knockdown, passage 3) was examined with an IncuCyte video-microscopy system (Essen Biosciences). For this assay, cells were seeded on a 96-well plate and grown to confluency, and a standardized scratch wound was made with a Woundmaker device according to the manufacturer's protocol. With live-cell imaging, wound closure was recorded in hourly intervals until the wound had fully closed. Subsequent data analysis was performed with the IncuCyte 96-well Kinetic Cell Migration and Invasion Assay software module. Each experiment comprised five averaged technical replicates of the same sample. The experiment was repeated three times independently, and the displayed data are representative.
Telomeric restriction fragment. Measurement of the length of the terminal restriction fragments was performed by Southern blotting as previously described 55 .
Statistical analysis. Statistical analysis was performed with Graph Pad Prism. Unpaired one-way ANOVA with two-tailed P values was combined with post hoc multivariate analysis according to Sidak to calculated statistical significance (F values and P values, as indicated in the figure legends). A standard confidence interval of 95% was applied in all analyses. Displayed in the figure are the mean values of all technical replicates for each of the independent experiments (displayed as single data points Data availability. At the time that the DNA samples used in this study were collected, patients did not provide consent for deposition of their genetic data in public databases. We therefore have not deposited the whole-exome sequencing data used in this study in a public database.
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This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. For more information, please read Reporting Life Sciences Research. List items are standard for all Nature journal articles but may not apply to all disciplines or manuscripts.
▸ Figure legends
• Check here to confirm that the following information is available in all relevant figure legends (or Methods section if too long):
• the exact sample size (n) for each experimental group/condition, given as a number, not a range;
• a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, culture, etc.);
• a statement of how many times the experiment shown was replicated in the laboratory;
• This checklist will not be published. Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the Methods section for statistics, reagents and animal models. Below, provide the page number or section and paragraph number (e.g. "Page 5" or "Methods, 'reagents' subsection, paragraph 2").
Corresponding Author Name: ________________________________________ Manuscript Number: ______________________________
▸ Statistics and general methods
Reported in section/paragraph or page #:
1. How was the sample size chosen to ensure adequate power to detect a pre-specified effect size? (Give section/paragraph or page #)
For animal studies, include a statement about sample size estimate even if no statistical methods were used. The study is on a rare disease. As stated in the METHODS section (page 19) 907 individuals with a relevant disease phenotype were examined.
Dr. Friedhelm Hildebrandt NG-LE44714-R n/a
As stated in the METHODS section (page 19), individuals with the relevant phenotype of steroid-resistent nephrotic syndrome were included in the study. These inclusion criteria were pre-established as the goal of the study was to identify novel monogenic causes of steroid-resistant nephrotic syndrome.
n/a n/a Phenotyping in mouse embryos and zebrafish larvae was performed blinded (the investigator had no knowledge of the genotype at that point in time). This is stated on page 20 of the METHODS section for both mice and fish. For all experiments it seem plausible to assume that.
▸ Human Subjects
11. Identify the committee(s) approving the study protocol.
12. Include a statement confirming that informed consent was obtained from all subjects.
13. For publication of patient photos, include a statement confirming that consent to publish was obtained.
14. Report the clinical trial registration number (at ClinicalTrials.gov or equivalent).
15. For phase II and III randomized controlled trials, please refer to the CONSORT statement and submit the CONSORT checklist with your submission.
16. For tumor marker prognostic studies, we recommend that you follow the REMARK reporting guidelines.
▸ Reagents
Reported in section/paragraph or page #: 6 . To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog number and/or clone number, supplementary information or reference to an antibody validation profile (e.g., Antibodypedia, 1DegreeBio). 10. We recommend consulting the ARRIVE guidelines (PLoS Biol. 8(6), e1000412,2010) to ensure that other relevant aspects of animal studies are adequately reported.
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